Thank you for subscribing!
Wise-Owl Aug 15, 2023
Our micro-cap cannabis and life sciences Investment Bod Science (ASX:BOD) has clinical trial results incoming. In less than two weeks we should know the results from the Phase IIb clinical trial for insomnia.
Next Investors Oct 25, 2021
Today Creso Pharma’s (ASX:CPH) announced the acquisition of a range of CBD brand and product assets that deliver anti-inflammatory relief to professional and amateur athletes suffering from chronic muscle and joint pain.
Finfeed Archived May 21, 2021
Creso Pharma (ASX: CPH) will enter the Polish animal health market after signing a Letter of Intent with Polvet Healthcare Teodorowski Spółka Jawna. It has also finalised the development of anibidiol® swine, a new and innovative hemp flour and oat bran based complementary feed product.
Finfeed Archived Apr 12, 2021
Cannabis centric healthcare company Bod Australia Limited (ASX: BDA) has announced the appointment of accomplished senior accounting and financial management executive Mr Alan Dworkin as Chief Financial Officer, effective 3rd May 2021.
Get expert stock analysis direct in your inbox
Finfeed Archived Apr 06, 2021
Creso Pharma (ASX: CPH) has appointed a US Director of Business Development just as New York State has legalised recreational cannabis. New York State is expected to become one of the largest recreational markets in the US valued at US$4.2BN.
Finfeed Archived Mar 26, 2021
Creso Pharma (ASX: CPH) has received firm commitments to raise $18M, a sum that significantly shores up its balance sheet. CPH will use the funds to progress a number of value accretive opportunities including Phase II and Phase III clinical trial initiatives with target acquisition company Halucenex Life Sciences Inc.
Finfeed Archived Mar 19, 2021
Creso Pharma Limited (ASX:CPH, FRA:1X8) has announced three new purchase orders for its wholly-owned Canadian subsidiary, Mernova Medicinal Inc, with a total value of C$177,122.40 (A$183,019.55).
Finfeed Archived Mar 02, 2021
Neurotech International Limited (ASX: NTI) has expanded its exclusive license with Dolce Cann Global Pty Ltd to now include all neurological disorders, disease or affliction affecting the human brain function, specifically - Autism, Epilepsy, ADHD, Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis, Transverse Myelitis, Inflammatory Brain disease, Fibromyalgia, Chronic Fatigue and Migraine.
Next Investors Mar 01, 2021
Creso Pharma (ASX: CPH | FRA: 1X8) is set to distribute its range of CBD and hemp animal health anibidiol® products throughout the US, following a deal signed with CERES Natural Remedies.
Join Our Mailing List
